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Abstract
Background: Mutations in DNA damage response factors BRCA1 and BRCA2 confer sensitivity to poly(ADP-ribose)
polymerase (PARP) inhibitors in breast and ovarian cancers. BRCA1/BRCA2-defective tumors can exhibit resistance to
PARP inhibitors via multiple mechanisms, one of which involves loss of 53BP1. Deficiency in the DNA damage
response factor ataxia-telangiectasia mutated (ATM) can also sensitize tumors to PARP inhibitors, raising the
question of whether the presence or absence of 53BP1 can predict sensitivity of ATM-deficient breast cancer to
these inhibitors.
Methods: Cytotoxicity of PARP inhibitor and ATM inhibitor in breast cancer cell lines was assessed by MTS, colony
formation and apoptosis assays. ShRNA lentiviral vectors were used to knockdown 53BP1 expression in breast
cancer cell lines. Phospho-ATM and 53BP1 protein expressions were determined in human breast cancer tissues by
immunohistochemistry (IHC).
Results: We show that inhibiting ATM increased cytotoxicity of PARP inhibitor in triple-negative and non-triple-negative
breast cancer cell lines, and depleting the cells of 53BP1 reduced this cytotoxicity. Inhibiting ATM abrogated homologous
recombination induced by PARP inhibitor, and down-regulating 53BP1 partially reversed this effect. Further, overall
survival was significantly better in triple-negative breast cancer patients with lower levels of phospho-ATM and tended to
be better in patients with negative 53BP1.
Conclusion: These results suggest that 53BP1 may be a predictor of PARP inhibitor resistance in patients with
ATM-deficient tumors.
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Background
Poly (ADP-ribose) polymerase (PARP) inhibitors have
shown therapeutic potential in patients with ovarian and
breast cancers associated with mutations in the breast and
ovarian susceptibility genes BRCA1 or BRCA2 [1–3]. One
randomized study in patients with relapsed high-grade
serous ovarian cancer (HSOC) who had previously
responded to platinum-based therapy found that
progression-free survival (PFS) was significantly higher
with the PARP inhibitor Olaparib (8.4 months) than with
placebo (4.8 months; hazard ratio, 0.35; P < 0.001). Subset
analysis showed greatest benefit in patients with germline
or somatic mutations in BRCA1 or BRCA2, in whom Ola-
parib prolonged PFS from 4.3 to 11.2 months (hazard ra-
tio, 0.18; P < 0.001) [2]. These and other results led the US
Food and Drug Administration to approve Olaparib for
advanced ovarian cancer involving BRCA mutations, mak-
ing it the first licensed PARP inhibitor drug.
PARP inhibitors compete with NAD+ binding, impair-
ing the ability of PARP to produce PAR chains [4, 5].
* Correspondence: wjiang6138@cicams.ac.cn; xubinghe@medmail.com.cn
†Equal contributors
3State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing, China
1Department of Medical Oncology, Cancer Institute and Hospital, Peking
Union Medical College and Chinese Academy of Medical Sciences, Beijing,
China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hong et al. BMC Cancer  (2016) 16:725 
DOI 10.1186/s12885-016-2754-7
Inhibition PARP-1 enzymatic activity results in the in-
ability to recruit the appropriate DNA repair factors to
the site of DNA damage, leading to SSB persistence, and
these SSBs convert to DSBs, which are repaired by the
error-free HR pathway at the replication fork [6]. Cells
with defective BRCA1 or BRCA2 are unable to perform
HR, so alternative repair processes kick in, such as non-
homologous DNA end-joining (NHEJ). These alternative
processes sometimes fail to repair DSBs, leading to gen-
ome instability and ultimately cytotoxicity. Conse-
quently, cells deficient in BRCA1 or BRCA2 are highly
sensitive to PARP-1 inhibition, which causes the accu-
mulation of DSBs [6, 7]. PARP inhibitor therapy is based
on synthetic lethality: it targets two separate molecular
pathways that are non-lethal when disrupted independ-
ently, but are lethal when inhibited simultaneously [8].
Both BRCA1 and BRCA2 function in the homologous
recombination (HR) pathway to repair of double-
stranded DNA breaks (DSBs), while PARP-1 is a key me-
diator in the base excision repair (BER) pathway to re-
pair single-stranded DNA breaks (SSBs) [9, 10].
Deficiency in several DNA damage response factors
other than BRCA1 and BRCA2 have also been shown to
be synthetically lethal with PARP inhibition [11, 12].
Screens based on short interfering RNA (siRNA) have
identified several genes, such as ataxia-telangiectasia
mutated (ATM), that when deleted sensitize tumor cells
to PARP inhibitors [12]. ATM is a DNA damage-
activated protein kinase and a member of the
phosphatidyl-inositol kinase-like kinase (PIKK) family,
which regulates responses to genotoxic stress, in particu-
lar DSBs [13]. In response to DNA damage, ATM auto-
phosphorylates at Ser1981 and this activated form
participates in cell cycle checkpoint arrest, DNA repair
and/or apoptosis [13] by triggering phosphorylation of
downstream effectors that include the checkpoint kinase
Chk2, DNA repair factors such as BRCA1 and transcrip-
tional regulators such as p53 [13, 14].
ATM alteration is most frequently seen in
hematological cancers. For example, nearly 50 % of cases
of mantle cell lymphoma contain mutations or deletions
in ATM [15, 16]. ATM alteration is also common in
solid tumors, including breast cancer, gastric and lung
cancer [17]. Disrupting ATM, either through mutation,
RNA interference or small-molecule inhibition, increase
the sensitivity of cancer cells to PARP inhibitors [12,
18–20]. This suggests that PARP inhibitors may have
therapeutic potential against ATM-deficient malignan-
cies. It also raises the question of what additional genetic
alterations may mediate or modulate synthetic lethality
of PARP and ATM inhibition.
A candidate genetic event that may affect this syn-
thetic lethality is loss of the DNA damage response fac-
tor 53BP1. So-called because it was first identified as a
p53-binding protein, 53BP1 participates in both HR and
NHEJ. 53BP1 stimulates NHEJ, whereas BRCA1 pro-
motes end resection and HR [21–23]. Loss of 53BP1 ap-
pears to render BRCA1/BRCA2-defective tumors
resistant to PARP inhibitors [21, 22], and studies in vitro
and in vivo suggest this is because loss of 53BP1 partially
restores the impaired HR in BRCA1-deficient cells [22].
This helps protect the genome and reduces the cytotox-
icity of PARP inhibitors and DNA-damaging agents. Sev-
eral BRCA1-deficient mouse mammary tumors that
initially responded to Olaparib and later became resist-
ant were shown to have lost 53BP1 and partially recov-
ered HR [24].
Here we examined whether ATM inhibition may
sensitize breast cancer lines to PARP inhibitors, as well
as whether the functional status of 53BP1 may affect the
sensitivity of ATM-deficient tumors to these inhibitors.
We show that ATM inhibition enhanced the sensitivity
of triple-negative and non-triple-negative breast cancer
cell lines to Olaparib, and 53BP1 knock-down partially
reversed this effect. ATM inhibition impaired HR in-
duced by PARP inhibitor, and 53BP1 down-regulation
partially restored HR. These results suggest that PARP
inhibitors may be therapeutically useful against ATM-
deficient breast cancer, and that the presence or absence
of 53BP1 may predict which ATM-deficient tumors are
likely to respond to such therapy.
Methods
Cell culture
Breast cancer cell lines CAL-51 and ZR-75-1 were cul-
tured in RPMI 1640 (Gibco) with 10 % FBS. Cell lines
MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SK-
BR-3 were cultured in DMEM (Gibco) containing 10 %
FBS. All cultures were maintained at 37 °C in a 5 % CO2
atmosphere.
Lentiviral transfection of target cells
Lentivirus encoding the short hairpin RNAs shRNA1
and shRNA2 targeting 53BP1 and the non-specific target
shRNA were designed and prepared by Genechem
(Shanghai, China). CAL-51 and MCF-7 cells were in-
fected with a pool of lentiviruses carrying shRNA1 or
shRNA2 and selected with 1 μg/mL puromycin for
10 days.
Inhibitor treatment
The PARP-1 inhibitor Olaparib (AZD2281) and ATM in-
hibitor KU55933 were purchased from Selleck Chemi-
cals. Compounds were serially diluted in DMSO and
finally diluted 103-fold in culture medium immediately
before use.
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Cell proliferation assay
Cells were seeded in 96-well plates at the appropriate
density for each cell line in 100 μl of medium and left at
room temperature for 30 min, after which they were in-
cubated overnight at 37 °C to allow attachment. Then
cells were incubated for 48 h at 37 °C with Olaparib at
concentrations of 0, 1, 2.5, 5, or 10 μM in the presence
or absence of 10 μM KU55933. During incubation with
inhibitors, the medium was not changed, nor were in-
hibitors added again.
Then 10 μl of MTS reagent (Promega, USA) was
added directly to the wells, and plates were incubated at
37 °C for at least 1 h. Absorbance was measured at
490 nm on a microplate reader (Bio-Rad 680, USA).
Background absorbance was first subtracted using a set
of wells containing medium only, then normalized to
and expressed as a relative percentage of the plate-
averaged DMSO control.
Colony formation assay
Cells (5 x 103) were seeded into 6-well culture plates
and incubated for 10 days at 37 °C in the presence of
Olaparib at 0, 2.5, 5, or 10 μM in the presence or ab-
sence of 10 μM KU55933. Cells were washed with pre-
chilled phosphate-buffered saline, fixed for 20 min with
pre-chilled methanol and stained for 15 min with crystal
violet. Colonies were examined and automatically
counted using G:box (SYNGENE). All experiments were
performed in triplicate.
Flow cytometry-based apoptosis assay
Human breast cancer cell lines CAL-51 and MCF-7
were treated for 48 h with DMSO vehicle, 10 μM
KU55933, 10 μM Olaparib, or the combination of
10 μM Olaparib and 10 μM KU55933. Cells were har-
vested by trypsinization, resuspended to a density of 1 ×
106 cells/mL in 1 × binding buffer, and stained with
FITC-Annexin V and propidium iodide (PI) using the
FITC Annexin V Apoptosis Detection Kit I (BD Biosci-
ences). Stained cells were analyzed using an LSRII flow
cytometer (Falcon BD, San Jose, CA, United States) ac-
cording to the manufacturer’s instructions. All experi-
ments were performed in triplicate.
Western blotting
Cells were harvested and lysed on ice for 40 min in RIPA
buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1 % Triton
X-100, 0.1 % Na-deoxycholate, 0.1 % SDS and 5 mM
EDTA) containing Complete Protease Inhibitor Cocktail
(Roche Applied Science). Total protein concentration
was determined using a colorimetric assay. Equal
amounts of total protein (60 μg) were separated by 6 %,
8 %, or 10 % SDS-PAGE and transferred to PVDF mem-
branes. Membranes were blocked with 2 % bovine serum
albumin (BSA), then incubated with primary antibodies
overnight at 4 °C. Primary antibodies from Cell Signaling
(Boston, MA, USA) were against caspase 3, cleaved cas-
pase 3, caspase 8, cleaved caspase 8, caspase 9, cleaved
caspase 9, PARP-1, cleaved PARP-1, Chk2, phospho-
Chk2 (Thr68), phospho-ATM (Ser1981) and γ-H2AX.
Primary antibodies from Abcam were against ATM and
Rad51. Primary antibody against β-actin (Sigma) pro-
vided a loading control. The membrane was then incu-
bated for 1 h with horseradish peroxidase-conjugated
goat anti-mouse IgG (1:2000) or goat anti-rabbit IgG
(1:3000) secondary antibody. The membrane was rinsed
in 1 × PBS containing 0.1 % Tween, then incubated with
chemiluminescence substrate. Blots were photographed
using an Image Reader LAS-4000 (Fujifilm) and ana-
lyzed using Multi Gauge 3.2.
Nuclear morphology assay
CAL-51 and MCF-7 cells were treated with DMSO,
10 μM Olaparib with or without 10 μM KU55933 re-
spectively for 48 h, washed three times with PBS, fixed
with methanol, and permeabilized with 0.1 % Triton X-
100. Then cells were stained with DAPI at 37 °C for
5 min in the dark. Stained cells were washed twice with
PBS before observed under fluorescence microscopy.
γ-H2AX focus formation assay
CAL-51 and MCF-7 cells were treated for 48 h with
DMSO vehicle or with Olaparib (5 or 10 μM) in the
presence or absence of 10 μM KU55933, then fixed with
4 % paraformaldehyde. Fixed cells were incubated for
1 h in 1 % BSA/10 % normal goat serum/0.3 M glycine
containing 0.05 % PBS-Tween in order to permeabilize
the cells and block non-specific protein–protein interac-
tions. Cells were incubated with anti-γ-H2AX antibody
(Cell Signaling), followed by Alexa Fluor® 488-
conjugated secondary antibody (ZSGB-BIO, Beijing,
China). Nuclei were stained using DAPI. Cells were visu-
alized using a non-confocal Operetta automated micro-
scope (Perkin Elmer). The number of γ-H2AX foci per
cell was quantified by ImageJ software. At least 200 cells
per experiment point were examined.
Clinical specimens
Formalin-fixed, paraffin-embedded (FFPE) tumor sam-
ples were obtained from breast cancer patients treated at
the Cancer Institute and Hospital of the Chinese Acad-
emy of Medical Sciences and Peking Union Medical Col-
lege. Clinical and follow-up data on the patients were
extracted from the clinical database. The use of clinical
specimens and data was approved by the local ethics
committee of the Cancer Institute and Hospital of Pe-
king Union Medical College.
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Immunohistochemistry of clinical specimens
FFPE samples of triple-negative breast cancer were
immunohistochemically stained with a monoclonal
antibody against phospho-ATM (1:100; rabbit IgG;
Epitomics, clone EP1890Y, S1981). This antibody binds
specifically to ATM phosphorylated Ser1981 [25]. Samples
were stained for 53BP1 using a rabbit polyclonal antibody
against 53BP1 (1:100; rabbit IgG; Santa Cruz Biotechnol-
ogy, clone H-300, catalog no. SC-22760). Slides were
deparaffinized with xylene and rehydrated in graded etha-
nol. Sections were submerged in EDTA antigenic retrieval
buffer (pH 8.0), microwaved to retrieve antigens, treated
with 3 % hydrogen peroxide in methanol to quench en-
dogenous peroxidase activity, and finally incubated with
1 % goat serum albumin to block non-specific binding.
Sections were incubated overnight at 4 °C with antibodies
against phospho-ATM or 53BP1, washed, then treated for
40 min with goat anti-mouse or -rabbit IgG conjugated to
horseradish peroxidase (ZSGB-BIO). The chromogen was
3,3′-diaminobenzidine.
Semi-quantitation of immunohistochemical results
Intensity of staining for phospho-ATM and 53BP1 was
scored as negative (0), weak positive (1), positive (2), and
strong positive (3). In addition, the proportion of cells
with each intensity score was recorded for each tissue
section. We defined phospho-ATM immunostaining as
‘high’ if at least 50 % of tumor cells had a nuclear stain-
ing intensity of at least 2. 53BP1 expression was defined
as negative if more than 90 % of tumor cells showed
negative nuclear staining (0). Immunostaining was semi-
quantitated in this way by two observers working inde-
pendently and blinded to clinical data. Inter-observer
agreement was >90 %. Discrepancies were re-examined
to obtain a consensus result.
Statistical analysis
Statistical analysis was carried out using SPSS 20 (IBM,
Chicago, IL, USA) or GraphPad Prism 5 for Windows,
with a significance threshold of p < 0.05. Results were
expressed as mean ± SEM, and differences were assessed
for significance using the two-tailed Student’s t test. The
two-tailed Pearson χ2 test or Fisher’s exact test was used
to identify associations of phospho-ATM or 53BP1 ex-
pression with clinicopathological parameters. Survival
curves were plotted using Kaplan-Meier analysis and com-
pared using the log-rank test. Factors associated with sur-
vival were identified using multivariate Cox regression.
Results
ATM inhibition sensitizes breast cancer cells to Olaparib
To evaluate whether ATM inhibition increases the cyto-
toxicity of PARP inhibitors, we treated both triple-
negative breast cancer cell lines (CAL-51, MDA-MB-231
and MDA-MB-468) and non-triple-negative breast can-
cer cell lines (MCF-7, T-47D and SK-BR-3) with increas-
ing concentrations of Olaparib (0–10 μM) alone or in
combination with 10 μM ATM inhibitor KU55933. All
cell lines had wild-type BRCA1 and BRCA2 genes; Add-
itional file 1: Table S1 summarizes the ER, PR, HER2,
BRCA1 and BRCA2 status of the lines. After 48-h incu-
bation with one or both inhibitors, cell viability was
assessed using the MTS assay. Olaparib induced ATM
phosphorylation at Ser1981, which was substantially
inhibited in the presence of KU55933 (Fig. 1a). This sug-
gests that ATM activation participates in the cellular re-
sponse to PARP inhibition. KU55933 significantly
increased Olaparib toxicity in the triple-negative cell line
CAL-51 and non-triple-negative cell line MCF-7
(Fig. 1b-c). Similar results were observed in the other
cell lines (Additional file 1: Figure S1A). Interestingly,
the three triple-negative cell lines appeared to be more
sensitive to Olaparib in the presence of KU55933 than
the three non-triple-negative cell lines. Olaparib inhib-
ited colony formation in CAL-51 and MCF-7 cells in a
dose-dependent manner, which KU55933 further en-
hanced it (Fig. 1d-e). Taken together, these data suggest
that Olaparib suppresses cell proliferation and colony
formation in breast cancer cell lines, and that KU55933
reinforces this effect through synthetic lethality.
Treatment with Olarparib, KU-55933 or both induced for-
mation of γ-H2AX foci
An early cellular response to DSBs is rapid phosphoryl-
ation of H2AX at Ser139, forming γ-H2AX foci [26].
H2AX phosphorylation plays a key role in signalling and
initiating the repair of DSBs, and the numbers of γ-
H2AX foci correlate closely with the number of DSBs
[27]. Treating breast cancer cell lines with both Olaparib
and KU55933 led to significantly more γ-H2AX foci for-
mation than treating them with either inhibitor alone
based on fluorescence microscopy (Fig. 2a-b). These
findings were further confirmed by Western Blot assay
(Fig. 2c). This provides further evidence that that Ola-
parib and Ku-55933 synthetically induce cellular DSBs.
ATM inhibition enhanced Olaparib-induced apoptosis in
MCF-7 and CAL-51 cells
Since the experiments above indicated that Olaparib and
KU55933 increased DSB formation, we wanted to know
whether they induced changes in nuclear morphology.
Such changes could reflect DSB-induced chromosome re-
arrangements or mutations, which can lead to apoptosis
or death [23]. Treating MCF-7 and CAL-51 cells for 48 h
with 10 μM Olaparib, 10 μM KU55933 or both led to nu-
clei with chromatin condensation and apoptotic bodies
detectable by DAPI fluorescence (Fig. 3a-b), with the com-
bination treatment causing more severe changes in
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nuclear morphology than either inhibitor alone. Similarly,
combination treatment caused significantly greater apop-
tosis than Olaparib alone, based on Annexin V/PI staining
followed by fluorescence-activated cell sorting (Fig. 3c-d).
In addition, Western blotting experiments showed that
combination treatment, as well as KU55933 treatment on
its own, up-regulated expression of apoptotic caspases 3,
8, and 9, and their cleaved forms and it stimulated PARP-
1 cleavage (Fig. 3e). These results suggest that Olarparib
and KU55933 activate apoptosis pathways.
53BP1 knock-down reduced the hypersensitivity of ATM-
inhibited cells to PARP inhibitor
Loss of 53BP1 reverses the hypersensitivity of BRCA1-de-
leted cells to the DNA cross-linker cisplatin by partially
restoring HR and thereby protecting the genome. ATM,
like BRCA1, plays a critical role in the DNA damage re-
sponse. ATM kinase is activated following PARP inhib-
ition and is required for PARP inhibitor induced HR.
Thus, we asked whether 53BP1 down-regulation might
render ATM-inhibited cells less sensitive to Olaparib.
The 53BP1 gene was stably knocked-down by transfect-
ing CAL-51 and MCF-7 cell lines with sh53BP1 lentivirus
particles. Particles were generated using two siRNAs to
ensure efficient knock-down. Stable transfectants, named
MCF-7-sh53BP1 and CAL-51- sh53BP1, were selected in
the presence of puromycin for 10 days and maintained as
polyclonal populations. Both transfected cell lines showed
much lower 53BP1 expression than the control-
transfected lines (Fig. 4a). Both transfected lines
Fig. 1 ATM inhibitor KU55933 sensitizes breast cancer cells to Olaparib a. Western Blot examined the protein level of phospho-ATM (Ser1981), ATM in
MCF-7 and CAL-51 cells 48 h after treatment of 10 μM Olaparib, 10 μM KU55933 or their combination, respectively. b, c MTS assay was used to determine
cell viability of CAL-51 and MCF-7 cells under different concentration of compounds treatments (0, 1, 2.5, 5, 10 μM Olaparib with or without 10 μM
KU55933, respectively) at 37 °C for 48 h. * means that there is statistical difference between the groups of Olaparib treatment with or without KU55933 at
each indicating concentration. d, e, Representative pictures (Up) and quantitative analysis (bottom) of colony formation assays. All experiments were
performed at least three times and data were statistically analyzed by two-tail t-test.*p< 0.05, ***p< 0.001. Error bars indicate S.E.M
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were also significantly less sensitive than control-
transfected lines to 10 μM Olaparib, 10 μM
KU55933 or both (Fig. 4b-c). Specifically, following
combination treatment, proliferation inhibition rates
were 20.3 % for MCF-7-sh53BP1 cells, 29.8 % for
MCF-7-ctrl cells, 46.5 % for CAL-51-sh53BP1 and
57.4 % for CAL-51-ctrl cells (Additional file 1: Fig-
ure S2). Similar results were obtained in the colony
formation assay (Fig. 4d-e). Taken together, our re-
sults suggest that 53BP1 deficiency renders ATM-
inhibited cells less sensitive to Olaparib.
Down-regulation of 53BP1 partially restored HR
It is well accepted that ATM, Chk2 and Rad51 are
critical regulators of HR DNA repair pathway. We
sought to investigate the protein levels of these fac-
tors under the treatment with Olaparib, KU55933 or
both. As is shown in Fig. 5a, Olaparib induced ATM
phosphorylation and activated its downstream effector
Chk2, and subsequently up-regulated Rad51. Adding
KU55933 inhibited the activation of ATM and Chk2
and down-regulated Rad51. Taken together, these ob-
servations suggest that Olaparib activated the HR
pathway and adding KU55933 inhibited it.
Previous studies have reported that knockdown of
53BP1 in BRCA1 deficient cells partially restored HR ac-
tivity [22, 23]. Interestingly, we found that knock-down
of 53BP1 also restored HR activity in ATM deficient
cells. Higher levels of phospho-ATM and Chk2 and up-
regulated RAD51 were observed in 53BP1 knock-down
cells than their control counterparts when treated with
Olaparib and KU55933 combined (Fig. 5b).
Phospho-ATM and 53BP1 expression and overall-survival
in triple-negative breast cancer
Our experiments link levels of phospho-ATM and
53BP1 to Olaparib sensitivity of breast cancer cell lines.
Further, we examined whether these levels might correl-
ate with survival of triple-negative breast cancer patients.
Immunohistochemistry of FFPE tumor samples from
73 patients with early triple-negative breast cancer
identified low expression levels of phospho-ATM in
44 (60.3 %) and high levels in 29 (39.7 %). Overall
survival was significantly better in patients with low
levels of phospho-ATM (Fig. 6a). After taking into ac-
count various clinical characteristics of the patients
(Additional file 1: Table S2), and adjusting for age,
tumor size, grade, number of metastatic lymph nodes
Fig. 2 Treatment of Olarparib, Ku-55933 or their combination induced γ-H2AX foci formation A, B, CAL-51 cells (a) and MCF-7 cells (b) were treated
with 0, 5, 10 μM Olaparib with or wihout 10 μM KU55933 respectively for 48 h and analyzed by immunofluorescence (IF) with γH2AX antibody. DAPI
was used to visualize cell nuclei. Representative pictures (left) and quantitative data (right) of the γ-H2AX foci. c, CAL-51 cells (left) and MCF-7 cells (right)
were treated with 0, 10 μM Olaparib with or wihout 10 μM KU55933 respectively 48 h and analyzed by Western Blot assay (WB) with γH2AX antibody.
All experiments were performed at least three times and data were statistically analyzed by two-tail t-test. ***p < 0.001. Error bars indicate S.E.M
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Fig. 3 (See legend on next page.)
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and lymphovascular invasion, multivariate analysis
identified phospho-ATM level as an independent pre-
dictor of overall survival (HR 1.83, 95%CI 1.063–
3.164, P = 0.029; Fig. 6b).
Immunohistochemistry of FFPE tumor samples from
another cohort of 92 patients with triple-negative
breast cancer identified 67 (72.8 %) as negative for
53BP1. Overall survival tended to be better among
these patients than among patients positive for
53BP1, but the difference did not achieve significance
(Fig. 6c). The clinicopathological characteristics of this
cohort are shown in Additional file 1: Table S3.)
(See figure on previous page.)
Fig. 3 ATM inhibition enhanced Olaparib induced apoptosis in MCF-7 and CAL-51 cells a, b, DAPI staining indicated the nuclear morphological
changes of CAL-51 cells (a) and MCF-7 cells (b). Cells were treated with 0, 10 μM Olaparib with or wihout 10 μM KU55933 respectively for 48 h.
Left, representative pictures; right, quantitative data. c, d, Annexin V/PI staining and FACS analysis revealed cell apoptosis of CAL-51 cells (c) and
MCF-7 cells (d). Cells were treated with 0, 10 μM Olaparib with or wihout 10 μM KU55933 respectively for 48 h. Left, representative pictures; right,
quantitative data. e, Western Blots showed that caspase 3, caspase 8, caspase 9 and their cleaved forms were increased after treatment with
10 μM Olaparib or 10 μM KU55933 or their combination in CAL-51 cells and MCF-7 cells. All experiments were performed at least three times and
data were statistically analyzed by two-tail t-test.*p < 0.05, **p < 0.01. Error bars indicate S.E.M
Fig. 4 Knock down of 53BP1 reduces the hypersensitivity of PARP inhibitor in ATM inhibited cells a, Western blot shown that 53BP1 was
efficiently knocked down by 53BP1 shRNA pool in CAL-51 cells and MCF-7 cells. b, c, MTS assays revealed the cell viability after treatment with in-
dicated compounds for 48 h in CAL-51-sh53BP1 cells and their control counterparts (b) or in MCF-7-sh53BP1 cells and control-transfected cells
(c). Left, cells were treated with 0, 5, 10 μM Olaparib. Right, cells were treated with 0, 5, 10 μM Olaparib combined with 10 μM KU55933. Cell via-
bility was normalized to the 0 μM Olaparib (DMSO) treatment group. d, e, Colony formation assays showed the cell colony formation capacity
after treatment with indicated compounds in CAL-51-sh53BP1 cells and their control counterparts (d) or in MCF-7-sh53BP1 cells and control-
transfected cells (e). Cells were treated with 0, 5, 10 μM Olaparib with or without 10 μM KU55933 for 10 days. Up, representative pictures; bottom,
quantitative data. All experiments were performed at least three times and data were statistically analyzed by two-tail t-test.*p < 0.05, **p < 0.01,
***p < 0.001. Error bars indicate S.E.M
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Discussion
PARP inhibitors have been studied most extensively in
HSOC and triple-negative breast cancer, and have proven
particularly effective against cancers associated with BRCA1
or BRCA2 mutations [28]. A phase II study in which
gemcitabine and carboplatin were used with PARP inhibitor
iniparib as neoadjuvant therapy in patients with triple-
negative breast cancer reported a pathologic complete
response rate of 56 % in cancer related to BRCA1/2 muta-
tions and 33 % in cancer associated with wild-type BRCA1/
Fig. 5 KU55933 reduced Olaparib induced ATM-Chk2 pathway activation and Rad51 up-regulation while knockdown 53BP1 supressed these
effects. a, Western blot assay showed the protein level of Rad51, Chk2, phospho-Chk2 (Thr68), ATM and phosphor-ATM (Ser1981) in CAL-51 and
MCF-7 cells after treatment with 10 μM Olaparib, 10 μM KU55933 and their combination respectively for 48 h. b, Western Blot assay showed the
protein level of Rad51, Chk2, phospho-Chk2 (Thr68), ATM and phosphor-ATM (Ser1981) in CAL-51-sh53BP1, MCF-7-sh53BP1 cells and their
control-transfected cells after synergistic treatment with 10 μM Olaparib and 10 μM KU55933. All experiments were performed at least
three times
Fig. 6 Association between phosphor-ATM or 53BP1 and overall survival in triple negative breast cancer (TNBC) samples A, Kaplan-Meier survival
analysis of early TNBC patients stratified by phosphor-ATM expression level. B, Different factors (including N stage, phosphor-ATM level, grade, T
stage, age and LVSI) were analyzed for their association with patient survival using Cox regression multivariate model. The hazard ratio and 95 %
CI are plotted for each factor. C, Kaplan-Meier survival curves of early TNBC patients stratified by 53BP1 expression level
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2 [29]. In addition to BRCA1/2 mutations, perhaps as many
as 35 % of patients with HSOC and triple-negative breast
cancer may have other HR pathway defects, such as
methylation-induced silencing of BRCA1/2, mutations in
other DNA repair genes, or activation of HR inhibitors.
This has led to the concept of “BRCAness” [30, 31],
highlighting the importance of identifying biomarkers to
detect HR defects, which may help predict types of cancer
likely to respond to PARP inhibitors.
ATM plays a pivotal role in the cellular DNA damage
response and is essential for maintaining genome stabil-
ity. Low levels of ATM are associated with higher sensi-
tivity to PARP inhibitors in several cancer cell lines [32].
ATM–deficient mantle-cell lymphoma and gastric can-
cer cells respond better to Olaparib than the ATM-
proficient cells [19]. In a phase II clinical trial, treating
gastric cancer patients with Olaparib and paclitaxel led
to a greater increase in overall survival among the sub-
group of patients with low ATM expression (HR 0.35,
80%CI 0.22 to 0.56, P < 0.002) than among the overall
population (HR 0.56, 80%CI 0.41 to 0.75, P = 0.005) [33].
In the present study, using KU55933 to reduce the level
of phospho-ATM sensitized breast cancer cell lines to
Olaparib. This result raised the possibility that phospho-
ATM level may predict sensitivity to PARP inhibitor in
breast cancer. To test this, we looked for an association
between survival of patients with early triple negative
breast cancer and phospho-ATM expression in their
tumor tissue. Using a cut-off of 50 % of tumor cells
showing positive nuclear staining, we obtained separable
overall survival curves f or patients above and below the
cut-off. Moreover, multivariate analysis identified
phospho-ATM level as an independent prognostic fac-
tor. Our results justify future clinical work to validate
phospho-ATM level in breast cancer tissue as a pre-
dictor of PARP inhibitor sensitivity.
Our results indicate that PARP and ATM inhibition
interact synergistically, reflecting the fact that both pro-
tein targets are involved in DNA damage repair and
therefore interact synthetically. The effect of combin-
ation therapy was greater in triple-negative breast cancer
cells than in non-triple-negative breast cancer lines. This
is not surprising given that the most frequent loss-of-
function and gain-of-function alterations in triple-
negative breast cancer involve genes associated with
DNA damage repair [34, 35]. Treating this type of breast
cancer remains a major challenge because it is a highly
heterogeneous disease [36] and no targeted therapy has
been approved to date. Our results suggest the potential
of combination treatment using PARP and ATM inhibi-
tors, which should be validated and further examined in
clinical trials.
In our study, 53BP1 down-regulation rendered ATM-
deficient cells less sensitive to PARP inhibitor. This is
consistent with a previous study showing that 53BP1
loss confers PARP inhibitor resistance in BRCA1-
deficient tumor cells [22]. Our results further show that
53BP1 knock-down increased RAD51 focus formation,
indicating partially restored HR. This is consistent with
previous studies that loss of 53BP1 partially restores the
impaired HR in BRCA1-deficient cells [22]. Given its
link with HR, 53BP1 should be evaluated as a potential
biomarker for identifying which patients will likely bene-
fit most from the combination of ATM And PARP in-
hibition. A better Olaparib efficacy in gastric cancer
patients with low ATM expression has been demonstrated
in a phase II study, and 75 % of gastric carcinoma cases
are reported to be 53BP1-positive34. In contrast, only
27.2 % of patients with triple-negative breast cancer in our
cohort were 53BP1-positive, similar to the 30 % reported
in a previous study [22] and lower than the 55 % reported
for ER-positive breast cancer tissue.
Conclusion
Overall, in our present study we confirmed that inhibit-
ing ATM increased cytotoxicity of PARP inhibitor in
breast cancer cell lines, and demonstrated for the first
time that depleting 53BP1 reduced this cytotoxicity. We
found that ATM inhibition abrogated homologous re-
combination induced by PARP inhibitor, and down-
regulating 53BP1 partially reversed this effect. Further,
overall survival was significantly better in triple-negative
breast cancer patients with lower levels of phospho-
ATM and tended to be better in patients with negative
53BP1. These findings indicated that 53BP1 might be a
predictor of PARP inhibitor resistance in patients with
ATM-deficient tumors.
Additional file
Additional file 1: Figure S1. Olaparib inhibited breast cancer cells
proliferation and KU55933 enhanced this effect. A ~ D, MTS assay was
used to determine cell viability of TNBC cell lines MDA-MB-231 (A),
MDA-MB-468 (B) and non-TNBC cell lines T-47D (C), SK-BR-3 (D) under
different concentration of compounds treatments (0, 1, 2.5, 5, 10 μM
Olaparib with or without 10 μM KU55933, respectively) at 37 °C for 48 h.
* means that there is statistical difference between the groups of
Olaparib treatment with or without KU55933 at each indicating
concentration. All experiments were performed at least three times and
data were statistically analyzed by two-tail t-test.*p < 0.05, **p < 0.01, ***p
< 0.001. Error bars indicate S.E.M. Figure S2. The inhibition effect of
Olaparib treatment or combined with KU-55933 in breast cancer cells.
MTS assays were performed to detecte the cell viability after treatment
with indicated compounds for 48 h in CAL-51-sh53BP1 cells and their
control counterparts or in MCF-7-sh53BP1 cells and control-transfected
cells. Inhibition rate was calculated and normalized to the 0 μM Olaparib
(DMSO) treatment group. The colors indicated the inhibition effect, blue,
the stronger color means less inhibition; red, the stronger color means
greater inhibition. Table S1. ER, PR, HER2, BRCA1 and BRCA2 status of
selected cell lines. Table S2. Clinical characteristics of the cohort tested
for pATM expression. Table S3. Clinical characteristics of the cohort
tested for 53BP1 expression. (DOCX 819 kb)
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